261 related articles for article (PubMed ID: 27079754)
1. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.
Jackman RP; Lee JH; Pei R; Bolgiano D; Lebedeva M; Slichter SJ; Norris PJ
Transfusion; 2016 Jun; 56(6):1442-50. PubMed ID: 27079754
[TBL] [Abstract][Full Text] [Related]
2. Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients.
Fontaine MJ; Kuo J; Chen G; Galel SA; Miller E; Sequeira F; Viele M; Goodnough LT; Tyan DB
Transfusion; 2011 Dec; 51(12):2611-8. PubMed ID: 21615749
[TBL] [Abstract][Full Text] [Related]
3. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.
Jackman RP; Deng X; Bolgiano D; Lebedeva M; Heitman JW; Busch MP; Slichter SJ; Norris PJ
Blood; 2013 Apr; 121(16):3261-6; quiz 3299. PubMed ID: 23393051
[TBL] [Abstract][Full Text] [Related]
4. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.
Gras C; Schulze K; Goudeva L; Guzman CA; Blasczyk R; Figueiredo C
Hum Gene Ther; 2013 Dec; 24(12):1018-28. PubMed ID: 24090417
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
Figueiredo C; Blaszczyk R
J Stem Cells; 2014; 9(3):149-61. PubMed ID: 25157449
[TBL] [Abstract][Full Text] [Related]
6. Technical Limitations of the C1q Single-Antigen Bead Assay to Detect Complement Binding HLA-Specific Antibodies.
Taylor CJ; Kosmoliaptsis V; Martin J; Knighton G; Mallon D; Bradley JA; Peacock S
Transplantation; 2017 Jun; 101(6):1206-1214. PubMed ID: 27306532
[TBL] [Abstract][Full Text] [Related]
7. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
[TBL] [Abstract][Full Text] [Related]
8. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
9. Comparison Between Total IgG, C1q, and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.
Moreno Gonzales MA; Mitema DG; Smith BH; Schinstock CA; Stegall MD; Wakefield LL; Henderson NA; DeGoey SR; Kreuter JD; Gandhi MJ
Transplant Proc; 2017 Nov; 49(9):2031-2035. PubMed ID: 29149956
[TBL] [Abstract][Full Text] [Related]
10. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization.
Ata P; Canbakan M; Kara M; Özel L; Ünal E; Titiz Mİ
Transplant Proc; 2012; 44(6):1652-5. PubMed ID: 22841237
[TBL] [Abstract][Full Text] [Related]
11. Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions.
Waterman HR; Kapp LM; Munday A; Odem-Davis K; Zimring JC
Transfusion; 2016 Jan; 56(1):91-100. PubMed ID: 26400622
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Complement-Binding Capacity of HLA Antibodies Based on Mean Fluorescence Intensity.
Zhao J; Fu YX; Yang T; Shen ZY; Wu CL
Transplant Proc; 2016; 48(6):2235-40. PubMed ID: 27569975
[TBL] [Abstract][Full Text] [Related]
14. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
Brubaker DB; Romine M
Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
[TBL] [Abstract][Full Text] [Related]
15. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
Hess JR; Trachtenberg FL; Assmann SF; Triulzi DJ; Kaufman RM; Strauss RG; Granger S; Slichter SJ
Vox Sang; 2016 Oct; 111(3):281-291. PubMed ID: 27185561
[TBL] [Abstract][Full Text] [Related]
17. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.
Cai J; Terasaki PI; Zhu D; Lachmann N; Schönemann C; Everly MJ; Qing X
Exp Mol Pathol; 2016 Feb; 100(1):45-50. PubMed ID: 26615783
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates.
Arnold ML; Dechant M; Doxiadis II; Spriewald BM
Tissue Antigens; 2008 Jul; 72(1):60-6. PubMed ID: 18588575
[TBL] [Abstract][Full Text] [Related]
20. Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies.
Lachmann N; Todorova K; Schulze H; Schönemann C
Transplantation; 2013 Mar; 95(5):694-700. PubMed ID: 23354296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]